The Association of Community Cancer Centers (ACCC) has named Thomas A. Gallo, MS, MDA, as the 2018-2019 president of ACCC. This was announced at the ACCC’s 44th Annual Meeting & Cancer Center Business Summit on March 16, 2018.
The Association of Community Cancer Centers (ACCC) has named Thomas A. Gallo, MS, MDA, as the 2018-2019 president of ACCC. This was announced at the ACCC’s 44th Annual Meeting & Cancer Center Business Summit on March 16, 2018.
“I’m honored and humbled to serve as president of the Association of Community Cancer Centers, the leading education and advocacy organization for the multidisciplinary cancer care team,” Gallo said in a statement.
Gallo is also the executive director of the Virginia Cancer Institute in Richmond, Virginia. This role includes responsibility for managing a 24-provider medical oncology practice and over 200 employees with 7 medical offices, ambulatory infusion centers, and laboratories.
He plans to work with the ACCC to find solutions for common stressors in the field of cancer treatment. The stress of caring for patients with cancer can be daunting and draining on the physical, intellectual, and emotional health of all members of the cancer care team, Gallo said.
“Unfortunately, burnout is a top-of-mind issue for many of us as oncology has become more complex with new and evolving treatment options, growing financial toxicity, and an increasingly burdensome healthcare system, just to name a few of the stressors,” Gallo added.
During his time as president, he plans to find the solutions his healthcare teams need. The most important goal is to develop a structure for staff that would be more productive and effective.
As a long-time member of the ACCC, Gallo knows what types of innovations other members have already found to be productive changes. “Over the coming months I look forward to learning from them and sharing their ideas and insights. Together we can find solutions,” he said.
Gallo has served as ACCC president-elect in 2017-2018, as well as on the Board of Trustees in 2004-2005. He is currently serving as part of the ACCC Governmental Affairs Committee and is also involved with other communities and organizations outside of ACCC.
He is also a member of the Board of Directors of MD Value Care, an ACO of independent physician practices, past president of the Executive Committee of the MGMA Administrators in Oncology-Hematology Assembly, a current member and former president of the Board of Directors of the Virginia Association of Hematologists and Oncologists, and a former board member of the Community Oncology Alliance.
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen